Renal hypertrophy is a ubiquitous concomitant of human and experimental diabetic nephropathy. We propose that the hypertrophic response is a necessary predisposing condition for the development of diabetic nephropathy. The goal of these studies os to gain an understanding at a cellular and molecular level of the mechanisms underlying diabetic glomerular hypertrophy; the relationship to """"""""compensatory"""""""" hypertrophy; and the role of transcapillary hydraulic forces in initiating diabetic glomerular hypertrophy. We will employ Northern blot analysis, in situ (mRNA) hybridization, immunoblot and immunocytochemical techniques to determine the cellular localization, relative content and temporal profile of the alterations in content of a number of potential molecular effectors and targets of the hypertrophic response: specifically, Tyr(P) modified proteins, and a series of mRNAs whose expression is likely to be relevant to the cell growth and tissue remodeling required for hypertrophy. These studies will be carried out in kidney from rats with streptozotocin diabetes and after uninephrectomy; moreover, we will determine the effects of the two kidney Goldblatt model on the parameters outlined above, so as to define how the evolution of the cellular response induced by diabetes os altered by systemic (and presumably glomerular) hyperperfusion (unclipped kidney) versus hypoperfusion (clopped kidney). In order to understand the regulatory mechanisms which underlie the changes we observe in the in vivo models, we will examine, in isolated glomerular cells, the response of these Tyr(P) and mRNA targets to treatment with a variety of hormones, growth factors, and second messenger analogs, singly and in combination. We will use these data to identify the cellular targets and intracellular mechanisms that are critical to the development of diabetic renal hypertrophy, so as to design selective and specific interventions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK041513-03
Application #
3242291
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Project Start
1990-03-01
Project End
1993-02-28
Budget Start
1992-03-01
Budget End
1993-02-28
Support Year
3
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Force, Thomas; Kuida, Keisuke; Namchuk, Mark et al. (2004) Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease. Circulation 109:1196-205
Goruppi, Sandro; Bonventre, Joseph V; Kyriakis, John M (2002) Signaling pathways and late-onset gene induction associated with renal mesangial cell hypertrophy. EMBO J 21:5427-36
Porcher, Christophe; Horowitz, Burton; Bayguinov, Orline et al. (2002) Constitutive expression and function of cyclooxygenase-2 in murine gastric muscles. Gastroenterology 122:1442-54
Horiguchi, K; Semple, G S; Sanders, K M et al. (2001) Distribution of pacemaker function through the tunica muscularis of the canine gastric antrum. J Physiol 537:237-50
Makkinje, A; Quinn, D A; Chen, A et al. (2000) Gene 33/Mig-6, a transcriptionally inducible adapter protein that binds GTP-Cdc42 and activates SAPK/JNK. A potential marker transcript for chronic pathologic conditions, such as diabetic nephropathy. Possible role in the response to persistent stress. J Biol Chem 275:17838-47
Pombo, C M; Tsujita, T; Kyriakis, J M et al. (1997) Activation of the Ste20-like oxidant stress response kinase-1 during the initial stages of chemical anoxia-induced necrotic cell death. Requirement for dual inputs of oxidant stress and increased cytosolic [Ca2+]. J Biol Chem 272:29372-9
Molnar, A; Theodoras, A M; Zon, L I et al. (1997) Cdc42Hs, but not Rac1, inhibits serum-stimulated cell cycle progression at G1/S through a mechanism requiring p38/RK. J Biol Chem 272:13229-35
Pombo, C M; Bonventre, J V; Molnar, A et al. (1996) Activation of a human Ste20-like kinase by oxidant stress defines a novel stress response pathway. EMBO J 15:4537-46
Morooka, H; Bonventre, J V; Pombo, C M et al. (1995) Ischemia and reperfusion enhance ATF-2 and c-Jun binding to cAMP response elements and to an AP-1 binding site from the c-jun promoter. J Biol Chem 270:30084-92
Pombo, C M; Bonventre, J V; Avruch, J et al. (1994) The stress-activated protein kinases are major c-Jun amino-terminal kinases activated by ischemia and reperfusion. J Biol Chem 269:26546-51

Showing the most recent 10 out of 12 publications